Prostaglandin E2 primes naive T cells for the production of anti‐inflammatory cytokines
- 5 December 1997
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 27 (12) , 3526-3531
Abstract
In addition to their capacity to induce pain, vasodilatation and fever, prostaglandins E (PGE) exert anti‐inflammatory activities by inhibiting the release of pro‐inflammatory cytokines by macrophages and T cells, and by increasing interleukin (IL)‐10 production by macrophages. We here report that PGE2, the major arachidonic acid metabolite released by antigen‐presenting cells (APC), primes naive human T cells for enhanced production of anti‐inflammatory cytokines and inhibition of pro‐inflammatory cytokines. Unfractionated as well as CD45RO−CD31+ sort‐purified neonatal CD4 T cells acquire the capacity to produce a large spectrum of cytokines after priming with anti‐CD3 and anti‐CD28 monoclonal antibodies (mAb), in the absence of both APC and exogenous cytokines. PGE2 primes naive T cells in a dose‐dependent fashion for production of high levels of IL‐4, IL‐10 and IL‐13, and very low levels of IL‐2, interferon (IFN)‐γ, tumor necrosis factor (TNF)‐α, and TNF‐β. PGE2 does not significantly increase IL‐4 production in priming cultures, whereas it suppresses IL‐2 and IFN‐γ. Addition of a neutralizing mAb to IL‐4 receptor in primary cultures, supplemented or not with PGE2, prevents the development of IL‐4‐producing cells but does not abolish the effects of PGE2 on IL‐10 and IL‐13 as well as T helper (Th)1‐associated cytokines. Addition of exogenous IL‐2 in primary cultures does not alter the effects of PGE2 on naive T cell maturation. Thus PGE2 does not act by increasing IL‐4 production in priming cultures, and its effects are partly IL‐4 independent and largely IL‐2 independent. Together with the recent demonstration that PGE2 suppresses IL‐12 production, our results strongly suggest that this endogenously produced molecule may play a significant role in Th subset development and that its stable analogs may be considered for the treatment of Th1‐mediated inflammatory diseases.Keywords
This publication has 38 references indexed in Scilit:
- Interleukin (IL)-6 Directs the Differentiation of IL-4–producing CD4+ T CellsJournal of Experimental Medicine, 1997
- CD31 (PECAM‐1) is a differentiation antigen lost during human CD4 T‐cell maturation into Th1 or Th2 effector cellsImmunology, 1996
- Oxpentifylline inhibits tumor necrosis factor‐α mRNA transcription and protects against arthritis in mercuric chloride‐treated Brown Norway ratsEuropean Journal of Immunology, 1995
- Human naive CD4 T cells produce interleukin‐4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditionsEuropean Journal of Immunology, 1995
- Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune EncephalomyelitisScience, 1994
- Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1‐ but not type 2‐associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis ratsEuropean Journal of Immunology, 1993
- A new view of prostaglandin E regulation of the immune responseImmunology Today, 1991
- The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune responseImmunology Today, 1988
- Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages.Journal of Experimental Medicine, 1978
- Effect of Prostaglandin E2 on Adjuvant ArthritisNature, 1969